25 XP   0   0   10

Cullinan Oncology LLC
Buy, Hold or Sell?

Let's analyze Cullinan Oncology LLC together

I guess you are interested in Cullinan Oncology LLC. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cullinan Oncology LLC. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Cullinan Oncology LLC

I send you an email if I find something interesting about Cullinan Oncology LLC.

Quick analysis of Cullinan Oncology LLC (30 sec.)










What can you expect buying and holding a share of Cullinan Oncology LLC? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$7.39
Expected worth in 1 year
$6.34
How sure are you?
31.0%

+ What do you gain per year?

Total Gains per Share
$-1.04
Return On Investment
-6.2%

For what price can you sell your share?

Current Price per Share
$16.78
Expected price per share
$15.20 - $30.19
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Cullinan Oncology LLC (5 min.)




Live pricePrice per Share (EOD)

$16.78

Intrinsic Value Per Share

$-44.58 - $-52.85

Total Value Per Share

$-37.20 - $-45.46

2. Growth of Cullinan Oncology LLC (5 min.)




Is Cullinan Oncology LLC growing?

Current yearPrevious yearGrowGrow %
How rich?$425.6m$552.8m-$90.8m-19.7%

How much money is Cullinan Oncology LLC making?

Current yearPrevious yearGrowGrow %
Making money-$33m$16.2m-$49.3m-149.1%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Cullinan Oncology LLC (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#136 / 966

Most Revenue
#940 / 966

Most Profit
#803 / 966

Most Efficient
#299 / 966
3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Cullinan Oncology LLC? (5 min.)

Welcome investor! Cullinan Oncology LLC's management wants to use your money to grow the business. In return you get a share of Cullinan Oncology LLC.

What can you expect buying and holding a share of Cullinan Oncology LLC?

First you should know what it really means to hold a share of Cullinan Oncology LLC. And how you can make/lose money.

Speculation

The Price per Share of Cullinan Oncology LLC is $16.78. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cullinan Oncology LLC.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cullinan Oncology LLC, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $7.39. Based on the TTM, the Book Value Change Per Share is $-0.26 per quarter. Based on the YOY, the Book Value Change Per Share is $0.29 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cullinan Oncology LLC.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.64-3.8%-0.57-3.4%0.281.7%-0.19-1.1%-0.12-0.7%
Usd Book Value Change Per Share-0.49-2.9%-0.26-1.6%0.291.7%0.412.4%0.261.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.49-2.9%-0.26-1.6%0.291.7%0.412.4%0.261.5%
Usd Price Per Share17.04-11.76-11.61-11.63-7.22-
Price to Earnings Ratio-6.61--5.23--3.65--481.92--299.12-
Price-to-Total Gains Ratio-34.79--11.64--14.95--37.00--37.00-
Price to Book Ratio2.31-1.49-1.21-1.42-0.88-
Price-to-Total Gains Ratio-34.79--11.64--14.95--37.00--37.00-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share16.78
Number of shares59
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.260.41
Usd Total Gains Per Share-0.260.41
Gains per Quarter (59 shares)-15.3524.24
Gains per Year (59 shares)-61.4196.96
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-61-7109787
20-123-1320194184
30-184-1930291281
40-246-2540388378
50-307-3150485475
60-368-3760582572
70-430-4370679669
80-491-4980776766
90-553-5590873863
100-614-6200970960

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.017.00.05.6%1.023.05.03.4%1.023.014.02.6%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%4.012.02.022.2%9.018.02.031.0%9.027.02.023.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.018.00.0%0.00.029.00.0%0.00.038.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%4.012.02.022.2%9.018.02.031.0%9.027.02.023.7%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Cullinan Oncology LLC

About Cullinan Oncology LLC

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-06-17 17:23:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of Cullinan Oncology LLC.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cullinan Oncology LLC earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cullinan Oncology LLC to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cullinan Oncology LLC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y4.8%-4.8%
5Y4.8%10Y2.9%+1.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--168.0%+168.0%
TTM--209.9%+209.9%
YOY--242.3%+242.3%
5Y4.8%-401.7%+406.5%
10Y2.9%-532.2%+535.1%
1.1.2. Return on Assets

Shows how efficient Cullinan Oncology LLC is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cullinan Oncology LLC to the Biotechnology industry mean.
  • -8.3% Return on Assets means that Cullinan Oncology LLC generated $-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cullinan Oncology LLC:

  • The MRQ is -8.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.3%TTM-6.8%-1.4%
TTM-6.8%YOY1.5%-8.3%
TTM-6.8%5Y-4.1%-2.7%
5Y-4.1%10Y-2,024.9%+2,020.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.3%-11.9%+3.6%
TTM-6.8%-11.9%+5.1%
YOY1.5%-11.3%+12.8%
5Y-4.1%-13.5%+9.4%
10Y-2,024.9%-14.9%-2,010.0%
1.1.3. Return on Equity

Shows how efficient Cullinan Oncology LLC is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cullinan Oncology LLC to the Biotechnology industry mean.
  • -8.7% Return on Equity means Cullinan Oncology LLC generated $-0.09 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cullinan Oncology LLC:

  • The MRQ is -8.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -7.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.7%TTM-7.2%-1.5%
TTM-7.2%YOY1.9%-9.1%
TTM-7.2%5Y-2.4%-4.8%
5Y-2.4%10Y-1.5%-0.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.7%-14.2%+5.5%
TTM-7.2%-15.7%+8.5%
YOY1.9%-14.3%+16.2%
5Y-2.4%-19.2%+16.8%
10Y-1.5%-19.7%+18.2%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of Cullinan Oncology LLC.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cullinan Oncology LLC is operating .

  • Measures how much profit Cullinan Oncology LLC makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cullinan Oncology LLC to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cullinan Oncology LLC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y5.4%-5.4%
5Y5.4%10Y3.4%+2.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--354.6%+354.6%
TTM--225.9%+225.9%
YOY--252.2%+252.2%
5Y5.4%-428.3%+433.7%
10Y3.4%-531.1%+534.5%
1.2.2. Operating Ratio

Measures how efficient Cullinan Oncology LLC is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cullinan Oncology LLC:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y0.001-0.001
5Y0.00110Y0.001+0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.004-3.004
TTM-3.332-3.332
YOY-3.502-3.502
5Y0.0015.271-5.270
10Y0.0016.915-6.914
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of Cullinan Oncology LLC.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cullinan Oncology LLC is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 20.33 means the company has $20.33 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cullinan Oncology LLC:

  • The MRQ is 20.329. The company is very able to pay all its short-term debts. +2
  • The TTM is 20.939. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ20.329TTM20.939-0.610
TTM20.939YOY16.961+3.979
TTM20.9395Y25.600-4.660
5Y25.60010Y15.895+9.704
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ20.3293.767+16.562
TTM20.9394.000+16.939
YOY16.9614.905+12.056
5Y25.6005.883+19.717
10Y15.8956.286+9.609
1.3.2. Quick Ratio

Measures if Cullinan Oncology LLC is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cullinan Oncology LLC to the Biotechnology industry mean.
  • A Quick Ratio of 36.11 means the company can pay off $36.11 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cullinan Oncology LLC:

  • The MRQ is 36.114. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 36.711. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ36.114TTM36.711-0.598
TTM36.711YOY27.750+8.961
TTM36.7115Y37.663-0.952
5Y37.66310Y23.378+14.285
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ36.1143.054+33.060
TTM36.7113.506+33.205
YOY27.7504.756+22.994
5Y37.6635.757+31.906
10Y23.3786.338+17.040
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of Cullinan Oncology LLC.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cullinan Oncology LLC assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cullinan Oncology LLC to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.05 means that Cullinan Oncology LLC assets are financed with 5.3% credit (debt) and the remaining percentage (100% - 5.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cullinan Oncology LLC:

  • The MRQ is 0.053. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.053. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.053TTM0.0530.000
TTM0.053YOY0.062-0.009
TTM0.0535Y0.342-0.289
5Y0.34210Y367.556-367.214
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0530.330-0.277
TTM0.0530.342-0.289
YOY0.0620.287-0.225
5Y0.3420.368-0.026
10Y367.5560.382+367.174
1.4.2. Debt to Equity Ratio

Measures if Cullinan Oncology LLC is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cullinan Oncology LLC to the Biotechnology industry mean.
  • A Debt to Equity ratio of 5.6% means that company has $0.06 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cullinan Oncology LLC:

  • The MRQ is 0.056. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.056. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.056TTM0.0560.000
TTM0.056YOY0.066-0.010
TTM0.0565Y0.036+0.020
5Y0.03610Y0.022+0.014
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0560.365-0.309
TTM0.0560.415-0.359
YOY0.0660.370-0.304
5Y0.0360.443-0.407
10Y0.0220.476-0.454
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of Cullinan Oncology LLC

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cullinan Oncology LLC generates.

  • Above 15 is considered overpriced but always compare Cullinan Oncology LLC to the Biotechnology industry mean.
  • A PE ratio of -6.61 means the investor is paying $-6.61 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cullinan Oncology LLC:

  • The EOD is -6.508. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.609. Based on the earnings, the company is expensive. -2
  • The TTM is -5.230. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.508MRQ-6.609+0.101
MRQ-6.609TTM-5.230-1.380
TTM-5.230YOY-3.652-1.577
TTM-5.2305Y-481.917+476.688
5Y-481.91710Y-299.121-182.796
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.508-2.341-4.167
MRQ-6.609-2.997-3.612
TTM-5.230-2.882-2.348
YOY-3.652-3.553-0.099
5Y-481.917-6.262-475.655
10Y-299.121-6.288-292.833
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cullinan Oncology LLC:

  • The EOD is -6.321. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.419. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.832. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.321MRQ-6.419+0.098
MRQ-6.419TTM-5.832-0.587
TTM-5.832YOY-4.852-0.980
TTM-5.8325Y-28.573+22.741
5Y-28.57310Y-17.735-10.838
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.321-2.932-3.389
MRQ-6.419-3.739-2.680
TTM-5.832-3.776-2.056
YOY-4.852-4.917+0.065
5Y-28.573-7.942-20.631
10Y-17.735-8.503-9.232
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cullinan Oncology LLC is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.31 means the investor is paying $2.31 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cullinan Oncology LLC:

  • The EOD is 2.272. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.307. Based on the equity, the company is underpriced. +1
  • The TTM is 1.489. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.272MRQ2.307-0.035
MRQ2.307TTM1.489+0.818
TTM1.489YOY1.208+0.280
TTM1.4895Y1.421+0.067
5Y1.42110Y0.882+0.539
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.2721.843+0.429
MRQ2.3072.249+0.058
TTM1.4892.301-0.812
YOY1.2082.412-1.204
5Y1.4213.782-2.361
10Y0.8824.212-3.330
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cullinan Oncology LLC.

3.1. Institutions holding Cullinan Oncology LLC

Institutions are holding 78.783% of the shares of Cullinan Oncology LLC.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-31MPM Oncology Impact Management LP13.270420.9535764826800
2024-03-31Bvf Inc5.54651.4976319670100
2024-03-31Blue Owl Capital Holdings LP5.07489.95642924842-495000-14.4744
2024-03-31Franklin Resources Inc4.67910.01462696762-584518-17.8137
2024-03-31BlackRock Inc4.21450.0012428993-33281-1.3516
2024-03-31Vanguard Group Inc3.07860.0006177434529020.1638
2024-03-31State Street Corporation2.47330.00111425459860055152.1134
2024-03-31Paradigm Biocapital Advisors LP2.33890.8086134801513480150
2024-03-31BRAIDWELL LP2.1530.68151240865-668000-34.9946
2024-03-31Nextech Invest AG2.11883.2987122114500
2024-03-31Morgan Stanley - Brokerage Accounts1.99990.0016115264423274525.3011
2024-03-31Deerfield Management Co1.97540.3375113853111385310
2024-03-31Dimensional Fund Advisors, Inc.1.72360.0046993377776198.4759
2024-03-31Adage Capital Partners Gp LLC1.64830.03069500009500000
2024-03-31Logos Global Management LP1.21460.96547000007000000
2024-03-31Geode Capital Management, LLC1.17520.0011677330216663.3044
2024-03-31Rubric Capital Management LP1.08780.315762692900
2024-03-31TANG CAPITAL MANAGEMENT LLC0.9911.0133571138-50000-8.0497
2024-03-31Deutsche Bank AG0.9530.004354927636920.6767
2024-03-31Orbimed Advisors, LLC0.89810.1615517606-27242-4.9999
Total 58.614840.049233782226+3477184+10.3%

3.2. Funds holding Cullinan Oncology LLC

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-04-30Franklin Biotechnology Discv A(acc)USD2.02611.93691167743-17800-1.5014
2024-04-30Vanguard Total Stock Mkt Idx Inv1.57880.0016909957-14021-1.5175
2024-03-31Franklin US Small Cap Growth Equity1.38750.460279970000
2024-03-31Franklin Small Cap Growth SMA1.38750.46027997007996662351958.8235
2024-04-30Franklin Small Cap Growth Adv1.38750.773579970000
2024-05-31SPDR® S&P Biotech ETF1.35640.2762781778-9202-1.1634
2024-04-30Franklin Biotechnology Discovery A1.08351.9281624451-1069-0.1709
2024-05-30iShares Russell 2000 ETF1.03390.02359587745320.7664
2024-04-30Vanguard Institutional Extnd Mkt Idx Tr0.93660.0148539789-121-0.0224
2024-04-30Xtrackers S&P 500 Swap ETF 1C0.53810.09231012200
2024-03-31Fidelity Small Cap Index0.44490.0163256428-8846-3.3347
2024-05-30iShares Russell 2000 Value ETF0.40990.0463236218-314-0.1328
2024-04-30CT American Smaller Coms(US) InstAccGBP0.34040.469919620433421.7328
2024-04-30Fidelity Extended Market Index0.33480.0143192948-1748-0.8978
2024-05-30iShares Biotechnology ETF0.32480.0605187208-708-0.3768
2024-04-30CT (Lux) American Smaller Com 9U USD0.31430.470718115896505.6266
2024-04-30DFA US Targeted Value I0.28360.034716344700
2024-05-31State St Russell Sm/Mid Cp® Indx NL Cl C0.28250.009116283800
2024-05-31Schwab US Small-Cap ETF™0.27990.022116133700
2024-04-30DFA US Micro Cap I0.23350.053213458700
Total 15.96457.16369201190+763361+8.3%

3.3. Insider Transactions

Insiders are holding 4.541% of the shares of Cullinan Oncology LLC.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-05-06Jennifer MichaelsonSELL5800028.07
2024-02-01Corrine SavillSELL4000016.18
2024-01-29Corrine SavillSELL4000014.09
2024-01-22Corrine SavillSELL1868412.14
2023-12-26Nadim AhmedSELL42729.24
2023-12-21Jeffrey Alan JonesSELL18608.5
2023-12-21Jeffrey TrigilioSELL19208.5
2023-12-18Jeffrey Alan JonesSELL3868.22
2023-12-18Jeffrey TrigilioSELL3988.22
2023-12-12Jeffrey TrigilioSELL19267.81
2023-12-12Jennifer MichaelsonSELL10687.81
2023-06-28Nadim AhmedSELL75911.4
2023-06-20Jeffrey Alan JonesSELL38712.94
2023-06-20Jeffrey TrigilioSELL39912.94
3rd party ad coffee SUPPORTERis ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cullinan Oncology LLC compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.490-0.260-47%0.287-271%0.411-219%0.255-292%
Book Value Per Share--7.3868.016-8%9.592-23%6.069+22%3.761+96%
Current Ratio--20.32920.939-3%16.961+20%25.600-21%15.895+28%
Debt To Asset Ratio--0.0530.0530%0.062-15%0.342-85%367.556-100%
Debt To Equity Ratio--0.0560.056-1%0.066-16%0.036+55%0.022+149%
Dividend Per Share----0%-0%-0%-0%
Eps---0.645-0.574-11%0.283-327%-0.192-70%-0.119-81%
Free Cash Flow Per Share---0.664-0.527-21%-0.681+3%-0.365-45%-0.274-59%
Free Cash Flow To Equity Per Share---0.645-0.354-45%-0.801+24%0.132-588%0.099-750%
Gross Profit Margin--1.0021.001+0%1.000+0%1.000+0%0.828+21%
Intrinsic Value_10Y_max---52.847--------
Intrinsic Value_10Y_min---44.582--------
Intrinsic Value_1Y_max---2.464--------
Intrinsic Value_1Y_min---2.418--------
Intrinsic Value_3Y_max---9.561--------
Intrinsic Value_3Y_min---9.084--------
Intrinsic Value_5Y_max---19.260--------
Intrinsic Value_5Y_min---17.691--------
Market Cap967101876.000-2%982086768.000677778192.000+45%668844891.000+47%670317765.000+47%416059302.414+136%
Net Profit Margin----0%-0%0.048-100%0.029-100%
Operating Margin----0%-0%0.054-100%0.034-100%
Operating Ratio----0%-0%0.001-100%0.001-100%
Pb Ratio2.272-2%2.3071.489+55%1.208+91%1.421+62%0.882+161%
Pe Ratio-6.508+2%-6.609-5.230-21%-3.652-45%-481.917+7192%-299.121+4426%
Price Per Share16.780-2%17.04011.760+45%11.605+47%11.631+47%7.219+136%
Price To Free Cash Flow Ratio-6.321+2%-6.419-5.832-9%-4.852-24%-28.573+345%-17.735+176%
Price To Total Gains Ratio-34.258+2%-34.789-11.643-67%-14.952-57%-36.999+6%-36.999+6%
Quick Ratio--36.11436.711-2%27.750+30%37.663-4%23.378+54%
Return On Assets---0.083-0.068-18%0.015-642%-0.041-50%-20.249+24397%
Return On Equity---0.087-0.072-18%0.019-554%-0.024-72%-0.015-83%
Total Gains Per Share---0.490-0.260-47%0.287-271%0.411-219%0.255-292%
Usd Book Value--425665000.000461987750.000-8%552856000.000-23%349782111.111+22%216786300.828+96%
Usd Book Value Change Per Share---0.490-0.260-47%0.287-271%0.411-219%0.255-292%
Usd Book Value Per Share--7.3868.016-8%9.592-23%6.069+22%3.761+96%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.645-0.574-11%0.283-327%-0.192-70%-0.119-81%
Usd Free Cash Flow---38247000.000-30393500.000-21%-39261250.000+3%-21034222.222-45%-13064118.241-66%
Usd Free Cash Flow Per Share---0.664-0.527-21%-0.681+3%-0.365-45%-0.274-59%
Usd Free Cash Flow To Equity Per Share---0.645-0.354-45%-0.801+24%0.132-588%0.099-750%
Usd Market Cap967101876.000-2%982086768.000677778192.000+45%668844891.000+47%670317765.000+47%416059302.414+136%
Usd Price Per Share16.780-2%17.04011.760+45%11.605+47%11.631+47%7.219+136%
Usd Profit---37148000.000-33087000.000-11%16239500.000-329%-11234388.889-70%-6986390.069-81%
Usd Revenue----0%-0%-1050284.1110%-651900.4830%
Usd Total Gains Per Share---0.490-0.260-47%0.287-271%0.411-219%0.255-292%
 EOD+3 -5MRQTTM+8 -22YOY+15 -155Y+10 -2310Y+13 -20

4.2. Fundamental Score

Let's check the fundamental score of Cullinan Oncology LLC based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.508
Price to Book Ratio (EOD)Between0-12.272
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than136.114
Current Ratio (MRQ)Greater than120.329
Debt to Asset Ratio (MRQ)Less than10.053
Debt to Equity Ratio (MRQ)Less than10.056
Return on Equity (MRQ)Greater than0.15-0.087
Return on Assets (MRQ)Greater than0.05-0.083
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Cullinan Oncology LLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5034.832
Ma 20Greater thanMa 5019.090
Ma 50Greater thanMa 10022.390
Ma 100Greater thanMa 20019.801
OpenGreater thanClose16.460
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets449,430
Total Liabilities23,765
Total Stockholder Equity425,665
 As reported
Total Liabilities 23,765
Total Stockholder Equity+ 425,665
Total Assets = 449,430

Assets

Total Assets449,430
Total Current Assets445,721
Long-term Assets3,709
Total Current Assets
Cash And Cash Equivalents 74,228
Short-term Investments 358,783
Other Current Assets 12,710
Total Current Assets  (as reported)445,721
Total Current Assets  (calculated)445,721
+/-0
Long-term Assets
Property Plant Equipment 3,249
Long-term Assets Other 460
Long-term Assets  (as reported)3,709
Long-term Assets  (calculated)3,709
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities21,925
Long-term Liabilities1,840
Total Stockholder Equity425,665
Total Current Liabilities
Short-term Debt 1,329
Accounts payable 3,707
Other Current Liabilities 16,889
Total Current Liabilities  (as reported)21,925
Total Current Liabilities  (calculated)21,925
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,840
Long-term Liabilities  (as reported)1,840
Long-term Liabilities  (calculated)1,840
+/- 0
Total Stockholder Equity
Common Stock4
Retained Earnings -238,005
Accumulated Other Comprehensive Income -331
Other Stockholders Equity 663,997
Total Stockholder Equity (as reported)425,665
Total Stockholder Equity (calculated)425,665
+/-0
Other
Capital Stock4
Cash and Short Term Investments 433,011
Common Stock Shares Outstanding 43,011
Liabilities and Stockholders Equity 449,430
Net Debt -71,059
Net Invested Capital 425,665
Net Working Capital 423,796
Property Plant and Equipment Gross 3,249
Short Long Term Debt Total 3,169



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-31
> Total Assets 
6
23
18
10
7
61
63
21
17
14
10
13
12
7
1
0
128
1
0
3
100,461
0
0
222,017
214,708
479,666
464,353
453,404
437,185
437,463
667,249
617,237
561,117
514,990
521,984
494,707
485,096
449,430
449,430485,096494,707521,984514,990561,117617,237667,249437,463437,185453,404464,353479,666214,708222,01700100,461301128017121310141721636171018236
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
128
1
0
3
100,091
104,661
104,661
221,730
212,278
447,293
344,467
328,838
296,564
322,312
622,841
582,075
474,472
399,031
512,117
476,712
480,191
445,721
445,721480,191476,712512,117399,031474,472582,075622,841322,312296,564328,838344,467447,293212,278221,730104,661104,661100,0913011280200000000000000
       Cash And Cash Equivalents 
1
1
3
0
1
0
1
2
4
3
2
2
2
3
0
0
36
1
0
0
63,250
0
0
165,997
168,198
293,537
123,670
88,105
430,863
76,118
353,563
242,657
550,118
122,128
512,117
64,847
98,434
74,228
74,22898,43464,847512,117122,128550,118242,657353,56376,118430,86388,105123,670293,537168,198165,9970063,250001360032223421010311
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
35,380
0
0
53,595
42,008
147,337
213,035
232,939
230,692
238,736
257,432
333,294
311,140
268,572
349,964
401,583
368,633
358,783
358,783368,633401,583349,964268,572311,140333,294257,432238,736230,692232,939213,035147,33742,00853,5950035,38000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
0
0
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,400
0
05,400000000000000000030030000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
370
0
0
287
2,430
32,373
119,886
124,566
140,621
115,151
44,408
35,162
86,645
115,959
9,867
17,995
4,905
3,709
3,7094,90517,9959,867115,95986,64535,16244,408115,151140,621124,566119,88632,3732,4302870037000000000000000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
182
157
157
146
130
115
102
89
77
1,258
1,126
5,288
5,304
5,058
4,659
3,991
3,532
3,249
3,2493,5323,9914,6595,0585,3045,2881,1261,258778910211513014615715718200000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32,111
119,637
124,330
140,397
94,178
43,182
29,414
80,882
110,442
18,631
13,545
0
0
0013,54518,631110,44280,88229,41443,18294,178140,397124,330119,63732,1110000000000000000000000000
       Other Assets 
0
0
0
0
0
9
10
9
9
9
8
8
7
0
0
0
0
0
0
0
0
141
141
141
2,300
147
147
147
6,322
19,715
100
0
459
0
459
0
0
0
0004590459010019,7156,3221471471472,3001411411410000000078899910900000
> Total Liabilities 
174
223
262
323
350
891
916
918
975
1,012
947
941
887
912
845
907
1,450
483
503
578
140,370
0
0
7,806
291,046
9,967
5,813
7,930
11,811
17,993
62,631
31,109
26,088
29,341
22,410
25,890
31,201
23,765
23,76531,20125,89022,41029,34126,08831,10962,63117,99311,8117,9305,8139,967291,0467,80600140,3705785034831,4509078459128879419471,012975918916891350323262223174
   > Total Current Liabilities 
37
67
42
65
36
49
33
49
68
48
50
70
72
83
81
114
1,067
211
217
248
2,523
5,966
5,966
7,732
14,320
9,894
5,743
7,863
11,746
17,257
62,035
27,117
22,498
26,171
19,676
23,444
28,137
21,925
21,92528,13723,44419,67626,17122,49827,11762,03517,25711,7467,8635,7439,89414,3207,7325,9665,9662,5232482172111,067114818372705048684933493665426737
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,088
1,088
0
0
286
330
0
0
0
0
0
0
0
0
0
1,323
533
696
1,599
3,403
3,537
3,469
1,440
1,329
1,3291,4403,4693,5373,4031,5996965331,323000000000330286001,0881,08800000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,088
1,088
0
0
286
330
0
0
0
0
0
0
0
0
0
804
0
0
178
1,849
1,885
1,922
0
0
001,9221,8851,84917800804000000000330286001,0881,08800000000000000
       Accounts payable 
37
67
42
65
36
49
33
49
68
48
50
70
72
83
81
114
156
211
217
248
934
4,463
4,463
3,487
9,679
3,879
1,510
2,024
3,169
6,306
3,099
1,516
2,660
2,031
2,493
951
2,493
3,707
3,7072,4939512,4932,0312,6601,5163,0996,3063,1692,0241,5103,8799,6793,4874,4634,463934248217211156114818372705048684933493665426737
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
912
0
0
0
1,589
410
410
4,245
4,641
6,015
4,233
5,839
8,577
9,628
58,403
24,905
18,239
20,737
1,030
1,578
24,204
16,889
16,88924,2041,5781,03020,73718,23924,90558,4039,6288,5775,8394,2336,0154,6414,2454104101,5890009120000000000000000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
137,847
0
0
74
276,726
73
70
67
65
736
596
3,992
3,590
3,170
2,734
2,446
3,064
1,840
1,8403,0642,4462,7343,1703,5903,99259673665677073276,7267400137,84700000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1,088
-1,088
0
0
-286
-330
0
0
0
0
0
0
0
0
0
-68
596
3,992
3,412
1,321
849
524
2,150
1,840
1,8402,1505248491,3213,4123,992596-68000000000-330-28600-1,088-1,08800000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
736
596
3,992
0
3,170
2,734
0
0
0
0002,7343,17003,99259673600000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,200
73
70
67
65
0
0
0
0
0
0
0
0
0
000000000656770732,200000000000000000000000000
> Total Stockholder Equity
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1,202
-1,245
-1,322
-482
-502
-575
-40,773
0
0
212,348
-77,642
466,901
455,549
443,386
422,576
418,702
604,538
586,128
535,029
485,649
499,574
468,817
453,703
425,665
425,665453,703468,817499,574485,649535,029586,128604,538418,702422,576443,386455,549466,901-77,642212,34800-40,773-575-502-482-1,322-1,245-1,20200000000000000
   Retained Earnings 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-2,793
-2,836
-2,913
-3,060
-3,080
-3,153
-41,540
-55,135
-55,135
-64,993
-93,339
-93,409
-109,045
-126,395
-158,909
-171,007
3,891
-20,913
-47,695
-105,657
-137,871
-177,054
-200,857
-238,005
-238,005-200,857-177,054-137,871-105,657-47,695-20,9133,891-171,007-158,909-126,395-109,045-93,409-93,339-64,993-55,135-55,135-41,540-3,153-3,080-3,060-2,913-2,836-2,79300000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-4
0
0
59
-2
-60
-115
-58
-838
-3,134
-3,633
-3,929
-2,601
-1,242
-1,625
-1,051
-129
-331
-331-129-1,051-1,625-1,242-2,601-3,929-3,633-3,134-838-58-115-60-25900-400000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
560,366
564,705
569,835
584,714
592,839
604,275
610,965
585,320
592,544
639,066
0
0
0
000639,066592,544585,320610,965604,275592,839584,714569,835564,705560,3660000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-310
Gross Profit-310-310
 
Operating Income (+$)
Gross Profit-310
Operating Expense-190,339
Operating Income-190,649-190,649
 
Operating Expense (+$)
Research Development148,156
Selling General Administrative42,493
Selling And Marketing Expenses42,141
Operating Expense190,339232,790
 
Net Interest Income (+$)
Interest Income21,627
Interest Expense-0
Other Finance Cost-0
Net Interest Income21,627
 
Pretax Income (+$)
Operating Income-190,649
Net Interest Income21,627
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-169,223-212,075
EBIT - interestExpense = -190,649
-167,284
-153,162
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-190,649-169,223
Earnings Before Interest and Taxes (EBITDA)-190,339
 
After tax Income (+$)
Income Before Tax-169,223
Tax Provision--14,122
Net Income From Continuing Ops-155,101-155,101
Net Income-153,162
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses190,649
Total Other Income/Expenses Net21,426-21,627
 

Technical Analysis of Cullinan Oncology LLC
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cullinan Oncology LLC. The general trend of Cullinan Oncology LLC is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cullinan Oncology LLC's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cullinan Oncology LLC.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 24.76 < 24.99 < 30.19.

The bearish price targets are: 16.19 > 15.57 > 15.20.

Tweet this
Cullinan Oncology LLC Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cullinan Oncology LLC. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cullinan Oncology LLC Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cullinan Oncology LLC. The current macd is -1.64430058.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cullinan Oncology LLC price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cullinan Oncology LLC. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cullinan Oncology LLC price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Cullinan Oncology LLC Daily Moving Average Convergence/Divergence (MACD) ChartCullinan Oncology LLC Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cullinan Oncology LLC. The current adx is 23.92.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Cullinan Oncology LLC shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Cullinan Oncology LLC Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cullinan Oncology LLC. The current sar is 18.88.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Cullinan Oncology LLC Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cullinan Oncology LLC. The current rsi is 34.83. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Cullinan Oncology LLC Daily Relative Strength Index (RSI) ChartCullinan Oncology LLC Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cullinan Oncology LLC. The current phase is Oversold in neutral market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cullinan Oncology LLC price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Cullinan Oncology LLC Daily Stochastic Oscillator ChartCullinan Oncology LLC Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cullinan Oncology LLC. The current cci is -64.57152388.

Cullinan Oncology LLC Daily Commodity Channel Index (CCI) ChartCullinan Oncology LLC Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cullinan Oncology LLC. The current cmo is -31.58939726.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Cullinan Oncology LLC Daily Chande Momentum Oscillator (CMO) ChartCullinan Oncology LLC Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cullinan Oncology LLC. The current willr is -83.80187416.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Cullinan Oncology LLC Daily Williams %R ChartCullinan Oncology LLC Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cullinan Oncology LLC.

Cullinan Oncology LLC Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cullinan Oncology LLC. The current atr is 1.43511506.

Cullinan Oncology LLC Daily Average True Range (ATR) ChartCullinan Oncology LLC Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cullinan Oncology LLC. The current obv is 22,583,251.

Cullinan Oncology LLC Daily On-Balance Volume (OBV) ChartCullinan Oncology LLC Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cullinan Oncology LLC. The current mfi is 36.99.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Cullinan Oncology LLC Daily Money Flow Index (MFI) ChartCullinan Oncology LLC Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cullinan Oncology LLC.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-30STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-05-01STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-05-02MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-05-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-05-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-05-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-05-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-06-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-06-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-20RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-06-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-27RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-07-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-03STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Cullinan Oncology LLC Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cullinan Oncology LLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5034.832
Ma 20Greater thanMa 5019.090
Ma 50Greater thanMa 10022.390
Ma 100Greater thanMa 20019.801
OpenGreater thanClose16.460
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cullinan Oncology LLC with someone you think should read this too:
  • Are you bullish or bearish on Cullinan Oncology LLC? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cullinan Oncology LLC? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cullinan Oncology LLC

I send you an email if I find something interesting about Cullinan Oncology LLC.


Stay informed about Cullinan Oncology LLC.

Receive notifications about Cullinan Oncology LLC in your mailbox!